Biliary tract cancer has long remained an area in which no new drug has been developed. Following targeted therapies, immunotherapies have led to remarkable advances in anticancer treatment, but biliary tract cancer has been neglected in terms of developing new drugs. This is because it has a lower prevalence rate than other cancers like lung cancer or stomach cancer, and even lower incidence in the West, which has been leading the development of new drugs.

In this area with minimal progress, AstraZeneca’s cancer immunotherapy Imfinzi obtained indication in Korea and abroad as a first-line treatment in biliary tract cancer. In Korea and abroad, Imfinzi became the first immunotherapy to be approved as a fi